1. Home
  2. CRBP vs OXSQ Comparison

CRBP vs OXSQ Comparison

Compare CRBP & OXSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$9.41

Market Cap

134.8M

Sector

Health Care

ML Signal

HOLD

Logo Oxford Square Capital Corp.

OXSQ

Oxford Square Capital Corp.

HOLD

Current Price

$1.74

Market Cap

151.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRBP
OXSQ
Founded
2009
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
134.8M
151.9M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
CRBP
OXSQ
Price
$9.41
$1.74
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$45.60
N/A
AVG Volume (30 Days)
182.7K
1.3M
Earning Date
06-15-2026
01-01-0001
Dividend Yield
N/A
24.00%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,822,272.00
N/A
Revenue This Year
N/A
$3.61
Revenue Next Year
$99.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
97.62
N/A
52 Week Low
$4.64
$1.56
52 Week High
$20.56
$2.66

Technical Indicators

Market Signals
Indicator
CRBP
OXSQ
Relative Strength Index (RSI) 57.91 42.32
Support Level $8.80 $1.68
Resistance Level $9.69 $1.94
Average True Range (ATR) 0.62 0.06
MACD 0.21 -0.01
Stochastic Oscillator 62.75 18.00

Price Performance

Historical Comparison
CRBP
OXSQ

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About OXSQ Oxford Square Capital Corp.

Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.

Share on Social Networks: